Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of ERIS Lifesciences Ltd
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 403 | 467 | 505 | 486 | 551 | 720 | 741 | 727 | 705 | 773 | 792 | 807 | 757 |
| Expenses + | 284 | 297 | 324 | 311 | 402 | 470 | 477 | 477 | 453 | 496 | 504 | 526 | 484 |
| Operating Profit | 119 | 170 | 181 | 176 | 148 | 250 | 265 | 250 | 252 | 277 | 288 | 282 | 272 |
| OPM % | 30% | 36% | 36% | 36% | 27% | 35% | 36% | 34% | 36% | 36% | 36% | 35% | 36% |
| Other Income + | 1 | 1 | 3 | 4 | 15 | 2 | 5 | 4 | 8 | 4 | 3 | -17 | 2 |
| Interest | 9 | 17 | 16 | 18 | 33 | 60 | 59 | 57 | 54 | 49 | 50 | 49 | 46 |
| Depreciation | 35 | 41 | 42 | 46 | 54 | 76 | 80 | 81 | 77 | 71 | 69 | 70 | 70 |
| Profit before tax | 76 | 112 | 126 | 116 | 77 | 116 | 129 | 116 | 129 | 161 | 173 | 145 | 159 |
| Tax % | 19% | 17% | 3% | 12% | -4% | 22% | 25% | 25% | 21% | 22% | 22% | 25% | -75% |
| Net Profit + | 61 | 94 | 122 | 101 | 80 | 90 | 96 | 87 | 102 | 125 | 134 | 109 | 279 |
| EPS in Rs | 4.81 | 6.98 | 9.07 | 7.55 | 5.22 | 6.12 | 6.73 | 6.15 | 6.89 | 8.66 | 8.82 | 7.32 | 20.33 |
Financials of ERIS Lifesciences Ltd
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 546 | 597 | 750 | 856 | 982 | 1,074 | 1,212 | 1,347 | 1,685 | 2,009 | 2,894 | 3,129 |
| Expenses + | 427 | 425 | 480 | 533 | 637 | 702 | 781 | 858 | 1,146 | 1,332 | 1,876 | 2,009 |
| Operating Profit | 118 | 172 | 269 | 322 | 345 | 372 | 431 | 489 | 539 | 677 | 1,018 | 1,120 |
| OPM % | 22% | 29% | 36% | 38% | 35% | 35% | 36% | 36% | 32% | 34% | 35% | 36% |
| Other Income + | 7 | 3 | 25 | 26 | 31 | 12 | 9 | 22 | 9 | 22 | 18 | -9 |
| Interest | 0 | 0 | 1 | 11 | 23 | 2 | 2 | 4 | 26 | 85 | 231 | 193 |
| Depreciation | 16 | 20 | 23 | 26 | 36 | 50 | 43 | 65 | 117 | 183 | 315 | 280 |
| Profit before tax | 109 | 154 | 270 | 312 | 317 | 331 | 394 | 442 | 405 | 431 | 489 | 639 |
| Tax % | 18% | 13% | 9% | 6% | 8% | 11% | 10% | 8% | 8% | 8% | 23% | -1% |
| Net Profit + | 89 | 135 | 247 | 295 | 291 | 297 | 355 | 406 | 374 | 397 | 375 | 648 |
| EPS in Rs | 6,489.45 | 9,714.18 | 17.95 | 21.39 | 21.15 | 21.84 | 26.16 | 29.88 | 28.10 | 28.82 | 25.84 | 44.72 |
| Dividend Payout % | -0% | 63% | -0% | -0% | -0% | 13% | 21% | 20% | 26% | -0% | 28% | 16% |
Financials of ERIS Lifesciences Ltd
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.14 | 0.14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
| Reserves | 266 | 299 | 553 | 848 | 1,137 | 1,283 | 1,563 | 1,895 | 2,182 | 2,573 | 2,841 | 3,889 |
| Borrowings + | 1 | 0 | 1 | 377 | 176 | -0 | 7 | 84 | 877 | 2,781 | 2,478 | 2,359 |
| Other Liabilities + | 91 | 98 | 124 | 170 | 175 | 205 | 202 | 233 | 337 | 1,366 | 1,412 | 1,104 |
| Total Liabilities | 357 | 397 | 692 | 1,408 | 1,502 | 1,502 | 1,785 | 2,226 | 3,410 | 6,734 | 6,744 | 7,366 |
| Fixed Assets + | 72 | 71 | 232 | 771 | 761 | 875 | 854 | 918 | 2,568 | 4,319 | 5,306 | 5,188 |
| CWIP | -0 | -0 | 0 | -0 | 3 | 4 | 2 | 27 | 22 | 20 | 67 | 171 |
| Investments | 167 | 190 | 303 | 365 | 356 | 78 | 294 | 520 | 37 | 16 | 67 | 62 |
| Other Assets + | 119 | 136 | 157 | 271 | 383 | 544 | 636 | 761 | 783 | 2,379 | 1,304 | 1,945 |
| Total Assets | 357 | 397 | 692 | 1,408 | 1,502 | 1,502 | 1,785 | 2,226 | 3,410 | 6,734 | 6,744 | 7,366 |
Financials of ERIS Lifesciences Ltd
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 90 | 131 | 200 | 235 | 223 | 271 | 375 | 378 | 292 | 486 | 1,065 | 538 |
| Cash from Investing Activity + | -92 | -44 | -184 | -590 | -5 | 123 | -323 | -320 | -975 | -1,828 | -78 | -369 |
| Cash from Financing Activity + | 0 | -84 | -24 | 363 | -221 | -335 | -82 | -45 | 688 | 1,380 | -881 | -314 |
| Net Cash Flow | -2 | 4 | -8 | 8 | -3 | 60 | -30 | 14 | 5 | 38 | 105 | -145 |
| Free Cash Flow | 77 | 108 | 150 | 210 | 186 | 125 | 350 | 258 | -550 | 357 | 910 | 241 |
| CFO/OP | 96% | 97% | 94% | 94% | 85% | 87% | 103% | 94% | 68% | 87% | 114% | 59% |
Financials of ERIS Lifesciences Ltd
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 16 | 16 | 24 | 28 | 31 | 53 | 42 | 44 | 63 | 77 | 58 | 79 |
| Inventory Days | 223 | 178 | 195 | 178 | 196 | 148 | 145 | 166 | 136 | 182 | 171 | 200 |
| Days Payable | 142 | 92 | 134 | 247 | 200 | 213 | 157 | 166 | 129 | 210 | 170 | 151 |
| Cash Conversion Cycle | 97 | 102 | 84 | -40 | 28 | -12 | 30 | 44 | 70 | 48 | 59 | 129 |
| Working Capital Days | 15 | 9 | 23 | -13 | -17 | 59 | 64 | 75 | 50 | -296 | -49 | -71 |
| ROCE % | 47% | 53% | 60% | 34% | 26% | 25% | 27% | 25% | 17% | 11% | 12% | 14% |